DANIEL ABRAMS, MD
Psychiatric at 16 Ave, Denver, CO
License number
Colorado 37971
Category
Psychiatric
Type
Psychiatry
Address
Address
12605 E 16Th Ave, Denver, CO 80045
Phone
(720) 848-0000
(303) 493-7000
(303) 493-7000
Personal information
See more information about DANIEL ABRAMS at radaris.comName
Address
Phone
9600 Castle Ridge Cir, Highlands Ranch, CO 80129
3576 Olive St, Denver, CO 80207
7600 E 6Th Ave, Denver, CO 80230
205 Crystal Park Rd, Manitou Springs, CO 80829
6050 1St Ave, Denver, CO 80220
Organization information
See more information about DANIEL ABRAMS at bizstanding.comDaniel Abrams MD
7600 E 6 Ave, Denver, CO 80230
Industry:
Psychiatrist, Neurologist, Neurosurgeon
Phone:
(303) 315-7928 (Phone)
Daniel Joseph Abrams
Professional information
See more information about DANIEL ABRAMS at trustoria.com
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
US Patent:
2009006, Mar 12, 2009
Filed:
Jul 25, 2008
Appl. No.:
12/180373
Inventors:
Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen E. Stevens - Westminster CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen E. Stevens - Westminster CO, US
International Classification:
A61K 31/7076, A61K 31/551, A61K 31/519, A61K 31/137, A61K 31/55, A61P 25/28
US Classification:
514 46, 514220, 51425941, 514651, 514217, 51421113
Abstract:
The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
US Patent:
2009020, Aug 20, 2009
Filed:
Jan 17, 2007
Appl. No.:
12/161149
Inventors:
Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen E. Stevens - Westminster CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen E. Stevens - Westminster CO, US
Assignee:
The Regents of the University of Colorado - Denver CO
International Classification:
A61K 31/7076, A61K 31/27, A61K 31/53, A61K 31/195, A61K 31/19, A61K 31/55, A61K 31/551, A61K 31/4178, A61K 31/135, A61P 25/18
US Classification:
514 46, 514483, 514242, 514562, 514557, 514217, 514220, 514397, 514646
Abstract:
The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
Central Administration Of Stable Formulations Of Therapeutic Agents For Cns Conditions
US Patent:
2012007, Mar 22, 2012
Filed:
Mar 18, 2011
Appl. No.:
13/051950
Inventors:
Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen Elizabeth Stevens - Westminster CO, US
Raymond Bunch - Phoenix AZ, US
Tom Anchordoquy - Lakewood CO, US
Karen Elizabeth Stevens - Westminster CO, US
Assignee:
The Regents of the University of Colorado - Denver CO
International Classification:
A61K 31/7076, A61K 31/53, A61K 31/196, A61K 31/55, A61K 31/19, A61K 31/551, A61K 31/4178, A61K 31/15, A61K 31/138, A61K 31/135, A61P 25/08, A61P 25/00, A61P 25/18, A61P 25/28, A61P 25/24, A61P 25/20, A61P 25/22, A61K 31/27
US Classification:
514 46, 514483, 514242, 514562, 514217, 514557, 514220, 514397, 514664, 514651, 514647, 514656
Abstract:
The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-ac-Live agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.
Dr. Daniel Abrams, Denver CO - MD (Doctor of Medicine)
Dr. Daniel Abrams, Denver CO - MD (Doctor of Medicine)
Specialties:
Psychiatry
Address:
Medical Psychiatry of Colorado
4500 E 9Th Ave SUITE 660, Denver 80220
(303) 395-4224 (Phone)
4500 E 9Th Ave SUITE 660, Denver 80220
(303) 395-4224 (Phone)
Procedures:
Neurological Surgery
Certifications:
Neurosurgery, 2001, Psychiatry, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Vanderbilt University School Of Medicine
Graduated: 1991
University Of Connecticut At Hartford
Memorial Sloan-Kettering Cancer Center
Vanderbilt University School Of Medicine
Graduated: 1991
University Of Connecticut At Hartford
Memorial Sloan-Kettering Cancer Center
Daniel Joseph Abrams, Denver CO
Daniel Joseph Abrams, Denver CO
Specialties:
Psychiatry, Neurological Surgery, Neurology
Work:
University of Colorado
4500 E 9Th Ave, Denver, CO 80220
4500 E 9Th Ave, Denver, CO 80220
Education:
Vanderbilt University (1991)
Ocular Parameter Sensing For Cerebral Perfusion Monitoring And Other Applications
Ocular Parameter Sensing For Cerebral Perfusion Monitoring And Other Applications
US Patent:
2007027, Nov 22, 2007
Filed:
Feb 15, 2007
Appl. No.:
11/675178
Inventors:
Daniel Abrams - Denver CO, US
Christopher Crowley - Golden CO, US
Kevin Keilbach - Boulder CO, US
Christopher Crowley - Golden CO, US
Kevin Keilbach - Boulder CO, US
International Classification:
A61B 5/00
US Classification:
600310000
Abstract:
A system and associated methodology allow for monitoring ocular parameters of a patient. Parameters that may be monitored in this regard include ocular perfusion, retinal oxygen saturation and ocular pressure. In one implementation, a device for monitoring the desired parameters includes a contact lens with fiber optic pathways mounted thereon. Light of multiple wavelengths can be transmitted into the patient's eyes via input optical pathways. Output optical pathways are associated with a camera for obtaining images of an area of interest within the patient's eyes. The images can be processed to obtain information regarding ocular perfusion and/or oxygen saturation. Changes in this regard can be used to identify a condition of interest.
Multi-Parameter Monitoring Device For Use With Central And Intravenous Administration Of Medication
Multi-Parameter Monitoring Device For Use With Central And Intravenous Administration Of Medication
US Patent:
2009022, Sep 3, 2009
Filed:
Jan 22, 2007
Appl. No.:
12/161302
Inventors:
Daniel J. Abrams - Denver CO, US
Raymond Bunch - Phoenix AZ, US
Michael Royals - Pierce CO, US
Raymond Bunch - Phoenix AZ, US
Michael Royals - Pierce CO, US
Assignee:
The Regents of the University of Colorado - Denver CO
International Classification:
A61M 5/142
US Classification:
604 66
Abstract:
The invention generally relates to a multi-parameter monitoring device for in-line use to monitor a therapeutic agent solution passing therethrough prior to being centrally administered in connection with treatment of a CNS-related condition or disorder, e.g., a neuro-psychiatric disorder. In another aspect, the invention relates to a multi-parameter monitoring device for in-line use to monitor a therapeutic agent solution passing therethrough prior to being (a) intravenously administered to a patient in connection with a treatment, such as is the case where the therapeutic agent solution comprises an IV administerable solution, or (b) administered to a patient in connection with a treatment for diabetes, such as is the case where the therapeutic agent comprises insulin.
Intra-Operative Ocular Parameter Sensing
Intra-Operative Ocular Parameter Sensing
US Patent:
2007019, Aug 16, 2007
Filed:
Dec 6, 2006
Appl. No.:
11/567597
Inventors:
Daniel Abrams - Denver CO, US
Christopher Crowley - Golden CO, US
Kevin Keilbach - Boulder CO, US
Christopher Crowley - Golden CO, US
Kevin Keilbach - Boulder CO, US
International Classification:
A61B 5/00
US Classification:
600310000
Abstract:
A patient is monitored during a medical procedure, such as spinal surgery, to identify a condition indicative of the possible onset of blindness or damage to the patient's eye or eyes. Parameters that may be monitored in this regard include ocular perfusion, retinal oxygen saturation and ocular pressure. In one implementation, a device for monitoring the desired parameters includes a contact lens with fiber optic pathways mounted thereon. Light of multiple wavelengths can be transmitted into the patient's eyes via input optical pathways. Output optical pathways are associated with a camera for obtaining images of an area of interest within the patient's eyes. The images can be processed to obtain information regarding ocular perfusion and/or oxygen saturation. Changes in this regard can be used to identify a condition of interest.